InChI
1S/C18H19NO3/c1-11(2)15-10-16(13(4)9-17(15)20)19-22-18(21)14-8-6-5-7-12(14)3/h5-11H,1-4H3/b19-16-
InChI key
CMOJHDQJJPIVEC-MNDPQUGUSA-N
assay
≥99% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
yellow
solubility
DMSO: 25 mg/mL, clear, yellow
shipped in
ambient
Quality Level
General description
A thymoquinone derivative, non-ATP competitive Polo-like Kinase 1 (Plk1) inhibitor specifically targeting the polo-box domain (PBD) of Plk1 (IC50) = 4.8 µM. Reduces both chromosome and kinetochoral localization of Plk1, induces chromosome congression defects , mitotic arrest in prometaphase, and apoptosis in HeLa cells at 25 µM. Exhibits anti-proliferative effects in a range of cancer cell lines, and in a mouse Xenograft model involving HeLa and MDA-MB-231 cells at 40 mg/kg.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Reindl, W., et al. 2008. Chem Biol.15, 459.
Yuan, J., et al. 2011, Am J Pathol179, 2091.
Yuan, J., et al. 2011, Am J Pathol179, 2091.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
11 - Combustible Solids
wgk
WGK 3
Sol-Bi Shin et al.
Journal of cellular physiology, 230(12), 3057-3067 (2015-05-16)
The expression of polo-like kinase 1 (Plk1) correlates with malignancy and is thus recognized as a target for cancer therapy. In addition to the development of ATP-competitive Plk1 inhibitors, the polo-box domain (PBD), a unique functional domain of PLKs, is
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持